CADD522 |
| Katalog-Nr.GC35576 |
CADD522 ist ein Inhibitor der RUNX2-DNA-Bindung (reguliert die RUNX2-vermittelte Transkription nachgeschalteter Zielgene herunter) mit einem IC50 von 10 nM. CADD522 hemmt das primÄre Tumorwachstum und die experimentelle Metastasierung von Tumorzellen in der Lunge von immungeschwÄchten MÄusen. CADD522 kann in der Krebsforschung verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 199735-88-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CADD522 is a potent inhibitor of runt-related transcription factor-2 (RUNX2)-DNA binding with an IC50 of 10 nM. CADD522 exhibits antitumor activity[1]. RUNX2-DNA binding[1]
[1]. Kim MS, et al. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017 Aug 10;8(41):70916-70940.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *